Digirad Corporation Reports Financial Results for the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
69
Digirad Corporation Reports Financial Results for the Fourth Quarter and Twelve Months ended December 31, 2016
  • Year over year fourth quarter revenue increases 100%
  • Year over year fourth quarter net income increases 192%
  • During 2016, Company pays down $11.7 million on its credit facility
  • Company continues to pay regular quarterly cash dividend of $0.05 cents per share

SUWANEE, Ga., Feb. 24, 2017 (GLOBE NEWSWIRE) -- Digirad Corporation (Nasdaq: DRAD ) today reported its financial results for the fourth quarter and twelve months ended December 31, 2016.

Total revenues for the fourth quarter were $31.1 million, an increase of 100 percent compared to the prior year’s fourth quarter revenues of $15.6 million.

Net income for the fourth quarter was $2.0 million, or $0.10 diluted earnings per share (EPS), compared to net income of $0.7 million, or $0.03 diluted EPS from the same period in the prior year.  Non-GAAP adjusted net income for the fourth quarter was $3.0 million, or $0.15 diluted EPS, compared to $1.3 million, or $0.07 diluted EPS from the same period in the prior year.

Non-GAAP adjusted EBITDA for the fourth quarter was $5.4 million, compared to $2.1 million in the same period in the prior year.

Total revenues for the twelve months ended December 31, 2016 were $125.5 million, an increase of 106 percent compared to the prior year’s revenues of $60.8 million.

Net income for the twelve months ended December 31, 2016 was $14.3 million, or $0.71 diluted EPS, compared to net income of $21.6 million, or $1.10 diluted EPS in the same period in the prior year.  Non-GAAP adjusted net income for the twelve months ended December 31, 2016 was $7.2 million, or $0.36 diluted EPS, compared to non-GAAP adjusted net income of $4.5 million, or $0.23 diluted EPS in the same period in the prior year.

Non-GAAP adjusted EBITDA for the twelve months ended December 31, 2016 was $16.8 million, compared to $7.2 million in the same period in the prior year. A reconciliation of non-GAAP adjusted net income and non-GAAP adjusted EBITDA is provided later in this release.

The results for the fourth quarter and twelve months ended December 31, 2016 include the results of the recent acquisition of DMS Health, which closed on January 1, 2016.

Digirad President and CEO Matt Molchan said, “We are very pleased with our results for the quarter, where we experienced exceptional product sales performance, as well as great performance from our service businesses, capping off a transformational year for Digirad.”

Molchan continued, “I am also pleased to report we have completed all of our operational integration activities related to the DMS Health acquisition, and will now be focusing our efforts on leveraging our combined resources as we move forward. Additionally, since entering our credit facility at the beginning of the year, we have paid down $11.7 million of the initial balance, including three extra principal payments. We continue to generate significant cash flow to maintain our stable dividend, fund organic growth and pursue accretive acquisitions.”

The Company previously announced a cash dividend of $0.05 cents per share that will be paid on February 28, 2017, to shareholders of record on February 15, 2017.

Conference Call Information

A conference call is scheduled for 10:00 a.m. EST on February 24, 2017 to discuss the results and management's outlook. The call may be accessed by dialing 1-877-407-9039 (international callers: +1-201-689-8470) five minutes prior to the scheduled start time and referencing Digirad. A simultaneous webcast of the call may be accessed online from the Events & Presentations link on the Investor Relations page at http://drad.client.shareholder.com ; an archived replay of the webcast will be available within 15 minutes of the end of the conference call.

Use of Non-GAAP Financial Measures by Digirad Corporation

This Digirad news release presents the non-GAAP financial measures “adjusted net income,” “adjusted net income per diluted share,” and “adjusted EBITDA.” The most directly comparable measure for these non-GAAP financial measures are net income and diluted net income per share. The Company has included below unaudited adjusted financial information, which presents the Company's results of operations after excluding acquired intangible asset amortization, goodwill impairment, acquisition related contingent consideration adjustments, investment impairment loss, transaction and integration costs associated with DMS Health Technologies, and non-recurring related income tax adjustments.  Further excluded in the measure of adjusted EBITDA are interest, taxes, depreciation, amortization and stock-based compensation.

A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding Digirad's financial condition and results of operations is included as Exhibit 99.2 to Digirad's report on Form 8-K filed with the Securities and Exchange Commission on February 24, 2017.

About Digirad Corporation

Digirad delivers convenient, effective, and efficient healthcare solutions on an as needed, when needed, and where needed basis.  Digirad’s diverse portfolio of mobile healthcare solutions and medical equipment and services, including diagnostic imaging and patient monitoring, provides hospitals, physician practices, and imaging centers through the United States access to technology and services necessary to provide exceptional patient care in the rapidly changing healthcare environment.  For more information, please visit www.digirad.com . 

Forward-Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Some of these forward-looking statements can be identified by the use of forward-looking words such as “believes,” “expects,” “may,” “will,” “should,” “seek,” “approximately,” “intends,” “plans,” “estimates,” or “anticipates,” or the negative of those words or other comparable terminology, or in specific statements such as the Company's ability to deliver value to customers, the ability to grow and generate positive cash flow, the ability to execute on restructuring activities, and ability to successfully execute acquisitions. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made. These risks are detailed in Digirad's filings with the U.S. Securities and Exchange Commission, including the Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other reports. Readers are cautioned to not place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Digirad undertakes no obligation to revise or update the forward-looking statements contained herein.

(Financial tables follow)

Digirad Corporation  Consolidated Statements of Operations (Unaudited)
 
  Three Months Ended   Twelve Months Ended
  December 31,   December 31,
(in thousands, except per share amounts) 2016   2015   2016   2015
               
Revenues:              
Services $ 23,015     $ 11,683     $ 95,511     $ 46,407  
Product and product-related 8,119     3,895     29,956     14,419  
Total revenues 31,134     15,578     125,467     60,826  
Cost of revenues:              
Services 18,720     9,048     75,515     35,968  
Product and product-related 3,772     1,838     14,179     6,949  
Total cost of revenues 22,492     10,886     89,694     42,917  
               
Gross profit 8,642     4,692     35,773     17,909  
Total gross profit percentage 27.8 %   30.1 %   28.5 %   29.4 %
Services gross profit percentage 18.7 %   22.6 %   20.9 %   22.5 %
Product and product-related gross profit percentage 53.5 %   52.8 %   52.7 %   51.8 %
               
Operating expenses:              
Marketing and sales 2,161     1,051     10,049     4,741  
General and administrative 4,088     3,009     19,988     9,888  
Amortization of intangible assets 578     134     2,313     506  
Goodwill impairment 338     —     338     —  
Total operating expenses 7,165     4,194     32,688     15,135  
               
Income from operations 1,477     498     3,085     2,774  
               
Other income (expense):              
Other income (expense), net 627     (233 )   212     (233 )
Interest expense, net (320 )   (12 )   (1,412 )   (24 )
Total other income (expense) 307     (245 )   (1,200 )   (257 )
               
Income before income taxes 1,784     253     1,885     2,517  
Income tax benefit 194     425     12,417     19,123  
Net income $ 1,978     $ 678     $ 14,302     $ 21,640  
               
Net income per share:              
Basic $ 0.10     $ 0.03     $ 0.73     $ 1.13  
Diluted $ 0.10     $ 0.03     $ 0.71     $ 1.10  
Dividends declared per common share $ 0.05     $ 0.05     $ 0.20     $ 0.20  
               
Weighted average shares outstanding – basic 19,764     19,404     19,594     19,210  
Weighted average shares outstanding – diluted 20,173     19,933     20,067     19,690  
Digirad Corporation  Consolidated Balance Sheets (Unaudited)
 
(in thousands) December 31,  2016   December 31,  2015
Assets:      
Current assets:      
Cash and cash equivalents $ 2,203     $ 15,868  
Securities available-for-sale 917     3,227  
Accounts receivable, net 14,503     7,274  
Inventories, net 5,987     4,381  
Restricted cash 1,376     233  
Other current assets 2,093     764  
Total current assets 27,079     31,747  
Property and equipment, net 31,407     6,252  
Intangible assets, net 11,628     3,079  
Goodwill 6,237     2,897  
Deferred tax assets 27,019     18,578  
Restricted cash 2,100     —  
Other assets 793     1,560  
Total assets $ 106,263     $ 64,113  
       
Liabilities:      
Current liabilities:      
Accounts payable $ 6,514     $ 1,369  
Accrued compensation 3,962     2,453  
Accrued warranty 196     213  
Deferred revenue 3,123     1,673  
Current portion of long-term debt 5,358     —  
Other current liabilities 3,520     2,998  
Total current liabilities 22,673     8,706  
Long-term debt, net of current portion 16,070     —  
Other liabilities 1,039     1,252  
Total liabilities 39,782     9,958  
       
Stockholders’ equity:      
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued or outstanding —     —  
Common stock, $0.0001 par value: 80,000,000 shares authorized; 19,892,557 and 19,416,070 shares issued and outstanding (net of treasury shares) at December 31, 2016 and 2015, respectively 2     2  
Treasury stock, at cost; 2,588,484 shares at December 31, 2016 and 2015 (5,728 )   (5,728 )
Additional paid-in capital 151,696     153,860  
Accumulated other comprehensive loss (52 )   (240 )
Accumulated deficit (79,437 )   (93,739 )
Total stockholders’ equity 66,481     54,155  
Total liabilities and stockholders’ equity $ 106,263     $ 64,113  
  Digirad Corporation Reconciliation of Non-GAAP Financial Measures (Unaudited)
   
      Three Months Ended December 31,   Twelve Months Ended December 31,
(in thousands, except per share amounts)   2016   2015   2016   2015
                   
Net income   $ 1,978     $ 678     $ 14,302     $ 21,640  
  Acquired intangible amortization   578     131     2,313     496  
  Acquisition related contingent consideration valuation adjustment (1)   (56 )   113     (64 )   (60 )
  Investment impairment loss (2)   —     278     414     278  
  Transaction and integration costs of DMS Health Technologies (3)   173     595     1,921     1,338  
  Goodwill impairment   338     —     338     —  
  Income tax items (4)   25     (446 )   (12,071 )   (19,145 )
Non-GAAP Adjusted net income   $ 3,036     $ 1,349     $ 7,153     $ 4,547  
                   
Net income per share - diluted (5)   $ 0.10     $ 0.03     $ 0.71     $ 1.10  
  Acquired intangible amortization   0.03     0.01     0.12     0.03  
  Acquisition related contingent consideration valuation adjustment (1)   —     0.01     —     —  
  Investment impairment loss (2)   —     0.01     0.02     0.01  
  Transaction and integration costs of DMS Health Technologies (3)   0.01     0.03     0.10     0.07  
  Goodwill impairment   0.02     —     0.02     —  
  Income tax items (4)   —     (0.02 )   (0.60 )   (0.97 )
Non-GAAP Adjusted net income per share - diluted (5)   $ 0.15     $ 0.07     $ 0.36     $ 0.23  
      Three Months Ended December 31,   Twelve Months Ended December 31,
(in thousands)   2016   2015   2016   2015
                   
Net income   $ 1,978     $ 678     $ 14,302     $ 21,640  
  Acquisition related contingent consideration valuation adjustment (1)   (56 )   113     (64 )   (60 )
  Investment impairment loss (2)   —     278     414     278  
  Transaction and integration costs of DMS Health Technologies (3)   173     595     1,921     1,338  
  Goodwill impairment   338     —     338     —  
  Depreciation and amortization   2,552     690     9,889     2,441  
  Stock-based compensation   270     166     1,024     616  
  Interest income   (2 )   (7 )   (14 )   (39 )
  Interest expense   322     19     1,426     63  
  Income tax benefit   (194 )   (425 )   (12,417 )   (19,123 )
Non-GAAP Adjusted EBITDA   $ 5,381     $ 2,107     $ 16,819     $ 7,154  
(1)   Reflects fair value adjustment to estimate of contingent consideration related to acquisitions.
(2)   Reflects impairment losses related to investment in Perma-Fix Medical.  Amount consists of a write-down of the investment to its fair market value that was considered other than temporary.
(3)   Reflects diligence, transaction, and integration costs related to the acquisition of DMS Health Technologies.
(4)   Reflects income tax effect for adjusted financial data and acquisition related income tax adjustments, and release of previously reserved net operating loss carryforwards.
(5)   Per share amounts are computed independently for each discrete item presented. Therefore, the sum of the quarterly per share amounts will not necessarily equal to the total for the year, and sum of individual items may not equal the total.
  Digirad Corporation Reconciliation of Non-GAAP Financial Measures (Unaudited)
   
      Three Months Ended
(in thousands, except per share amounts)   December 31, 2015   March 31, 2016   June 30, 2016   September 30, 2016   December 31, 2016
                       
Net income (loss)   $ 678     $ 11,609     $ 998     $ (283 )   $ 1,978  
  Acquired intangible amortization   131     577     578     578     578  
  Acquisition related contingent consideration valuation adjustment (1)   113     —     (3 )   (5 )   (56 )
  Investment impairment loss (2)   278     —     —     414     —  
  Transaction and integration costs of DMS Health Technologies (3)   595     1,450     171     127     173  
  Goodwill impairment   —     —     —     —     338  
  Income tax items (4)   (446 )   (12,333 )   67     170     25  
Non-GAAP Adjusted net income   $ 1,349     $ 1,303     $ 1,811     $ 1,001     $ 3,036  
                       
Net income (loss) per share - diluted (5)   $ 0.03     $ 0.58     $ 0.05     $ (0.01 )   $ 0.10  
  Acquired intangible amortization   0.01     0.03     0.03     0.03     0.03  
  Acquisition related contingent consideration valuation adjustment (1)   0.01     —     —     —     —  
  Investment impairment loss (2)   0.01     —     —     0.02     —  
  Transaction and integration costs of DMS Health Technologies (3)   0.03     0.07     0.01     0.01     0.01  
  Goodwill impairment   —     —     —     —     0.02  
  Income tax items (4)   (0.02 )   (0.62 )   —     0.01     —  
Non-GAAP Adjusted net income per share - diluted (5)   $ 0.07     $ 0.07     $ 0.09     $ 0.05     $ 0.15  
      Three Months Ended
(in thousands)   December 31, 2015   March 31, 2016   June 30, 2016   September 30, 2016   December 31, 2016
                       
Net income (loss)   $ 678     $ 11,609     $ 998     $ (283 )   $ 1,978  
  Acquisition related contingent consideration valuation adjustment (1)   113     —     (3 )   (5 )   (56 )
  Investment impairment loss (2)   278     —     —     414     —  
  Transaction and integration costs of DMS Health Technologies (3)   595     1,450     171     127     173  
  Goodwill impairment   —     —     —     —     338  
  Depreciation and amortization   690     2,465     2,383     2,489     2,552  
  Stock-based compensation   166     223     257     274     270  
  Interest income   (7 )   (5 )   (4 )   (3 )   (2 )
  Interest expense   19     375     383     345     322  
  Income tax expense (benefit)   (425 )   (12,461 )   37     202     (194 )
Non-GAAP Adjusted EBITDA   $ 2,107     $ 3,656     $ 4,222     $ 3,560     $ 5,381  
(1)   Reflects fair value adjustment to estimate of contingent consideration related to acquisitions.
(2)   Reflects impairment losses related to investment in Perma-Fix Medical.  Amounts consist of impairment of a Supply Agreement entered into between the two parties, a loss related to the initial excess of the transaction price over fair value and a write-down of the investment to its fair market value that was considered other than temporary.
(3)   Reflects diligence, transaction, and integration costs related to the acquisition of DMS Health Technologies.
(4)   Reflects income tax effect for adjusted financial data and acquisition related income tax adjustments, and release of previously reserved net operating loss carryforwards.
(5)   Per share amounts are computed independently for each discrete item presented. Therefore, the sum of the quarterly per share amounts will not necessarily equal to the total for the year, and sum of individual items may not equal the total.
Digirad Corporation Supplemental Debt Information (Unaudited)
 
The following table reflects outstanding principal balances and interest rates under the Company's credit facility at December 31, 2016:
 
(in thousands) Balance Interest Rate
Term A (1) $ 17,382   3.15 %
Term B (2) 4,581   5.65 %
Revolver —   2.69 %
Total borrowing $ 21,963    
(1)   Term A amortizes over a 7-year period with scheduled amortization ending in January 2021, with the remaining amount due in a balloon payment.
(2)   Term B amortizes over a 3-year period with scheduled amortization ending in January 2019. Through December 31, 2016, the Company has made three extra payments in the same amount as the scheduled payments.
Digirad Corporation Supplemental Cash Flow Information (Unaudited)
 
  Twelve Months Ended December 31,
(in thousands) 2016 2015 2014
Net cash provided by operating activities $ 10,834   $ 3,720   $ 4,280  
       
Purchases of property and equipment $ 6,185   $ 1,424   $ 1,258  

 

For more information contact: Jeff Keyes Chief Financial Officer 858-726-1600 ir@digirad.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 102

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
Gary Brecka's Longevity Centers Set to Launch with Impact

Updated Category News Views 0

A Footprint of Longevity in the Making It's not every day you see a name like Daymond John, of Shark Tank fame, getting his hands into the business of human longevity. But here we are, with Gary Brecka's Ultimate Longevity Center (ULC) getting ready to open its first centers come January 2027, in Arizona, Colorado, Florida, and Southern California. More than 300 U.S....

Continue Reading
SahajMobile's $25M Boost: Impact on Bangladesh Market

Updated Category News Views 0

Untapped Digital Frontier in Bangladesh There's an undeniable buzz around SahajMobile's recent $25 million credit facility, and it's one worth dissecting. This shot of capital, lined up with ALMA as part of SahajMobile’s Series A gamble, is setting the stage for a real shuffle in Bangladesh's digital landscape. Plugging into a Market Gap Ever since it hit the ground...

Continue Reading
Rock Tech Uncovers Major Lithium Discovery at Victory

Updated Category News Views 28

Rock Tech's Game-Changer at Victory Folks, we've got a shake-up in the lithium landscape over in Ontario, courtesy of Rock Tech Lithium Inc. They just unearthed something quite promising at their Victory Project: a spanking new spodumene-bearing pegmatite discovery. Now I know, if you're like me, you're thinking, 'What's the angle here?' Well, this isn't just another hole...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 116

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 215

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Peptide Tracker Refresh Unveils New Planning Features

Updated Category News Views 0

Peptide Tracker's Latest Updates: A Game Changer? I'll tell you what—if you're keeping tabs on your peptide intake like a seasoned gardener checks the soil, Peptide Tracker's fresh versions 3.2.0 and 3.3.0 might just be your new best mates. With the addition of washout scheduling and a robust six-month schedule preview, this isn't just another fancy tech update. It's...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 39

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 126

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 49

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Line-Up of Athletes for Future Games in Abu Dhabi

Updated Category News Views 298

Global Stars Confirmed for Games of the Future 2025 Some of the biggest names in phygital sports and esports from around the world will head to Abu Dhabi for the ultimate showdown in next-gen sports from 18-23 December. Phygital International, the UAE-based promoter of phygital sports globally, has just confirmed the lineup for the Games of the Future Abu Dhabi 2025 (GOTF...

Continue Reading
Rhythm Pharmaceuticals Earnings Report: What to Watch For

Updated Category News Views 239

Eyes on Rhythm Pharmaceuticals: Earnings Just Around the Corner A steady hum of anticipation is in the air as Rhythm Pharmaceuticals (NASDAQ:RYTM) gears up to unveil its quarterly earnings on February 26, 2026. While investors hung onto the last report’s fallout, expectations this time are swirling around whether RYTM can turn things around after a slip last quarter....

Continue Reading
First Capital REIT Reports Impressive Q3 2024 Growth Metrics

Updated Category News Views 239

First Capital REIT's Strong Q3 Results Highlight Robust Performance First Capital Real Estate Investment Trust (TSX: FCR) has announced remarkable financial results for the third quarter ending September 30, indicating robust operational performance backed by strong leasing activities. The detailed report is made accessible to investors on the Trust's official website....

Continue Reading
Sherwin-Williams Faces Challenges After Lowering Earnings Outlook

Updated Category News Views 168

Sherwin-Williams Adjusts Earnings Projections Following Q2 Results The Sherwin-Williams Company (NYSE: SHW) recently faced some challenges after reporting lower-than-expected second-quarter earnings. With adjusted earnings per share (EPS) of $3.38, the results fell short of Wall Street's predictions, which had estimated $3.81 per share. The company's quarterly revenue,...

Continue Reading
Oculis Financial Results & Clinical Update for Q2 2024

Updated Category News Views 108

Oculis Reports Q2 Financial Results and Company Update Oculis Holding AG (NASDAQ: OCS; XICE: OCS), a global biopharmaceutical company focused on improving eye care, has shared its latest financial results and significant developments. The highlights from the second quarter ending June 30, 2024, illustrate the company's dedication to advancing its innovative clinical...

Continue Reading